Tag: NOVEL

  • Gaboxadol (THIP)

    Selective extrasynaptic GABA-A delta-subunit agonist

    A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

    Abstract

    Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tofisopam

    2,3-benzodiazepine atypical anxiolytic

    A 2,3-benzodiazepine without classical GABA-A activity; a non-sedating anxiolytic marketed in Europe.

    Abstract

    Tofisopam (1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; CAS 22345-47-7; molecular formula C22H26N2O4; molecular weight 382.46) is a 2,3-benzodiazepine developed at EGIS (Hungary) in the 1960s and approved in Hungary, France, and other European and Asian markets under the trade name Grandaxin. Distinct from the 1,4-benzodiazepine class (diazepam, lorazepam, etc.) by the position of the nitrogens in the diazepine ring: the 2,3 isomer does not bind the classical benzodiazepine site on GABA-A receptors and lacks the GABA-A-mediated sedation, anxiolysis, and dependence of conventional benzodiazepines. The mechanism is incompletely characterized; possibilities include phosphodiesterase IV inhibition and modulation of dopaminergic signaling. Plasma half-life is approximately 6 to 8 hours; metabolism is hepatic. Approved indications in markets where registered include anxiety disorders, autonomic instability, and post-stress recovery; off-label use in fatigue and reactive depression. Not approved in the US. Used as a reference 2,3-benzodiazepine.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mexidol (Emoxypine)

    Pyridine antioxidant

    A Russian-developed pyridine antioxidant (2-ethyl-6-methyl-3-hydroxypyridine succinate) widely prescribed in Russia for cerebrovascular and cognitive disorders.

    Abstract

    Mexidol (Emoxypine succinate; 2-ethyl-6-methyl-3-hydroxypyridine succinate; CAS 127464-43-1) is a pyridine-class antioxidant developed in the Soviet Union in the 1980s and approved in Russia for cerebrovascular insufficiency, cognitive impairment, and acute neurological events including stroke. The compound combines a 3-hydroxypyridine antioxidant (emoxypine) with succinate as the metabolic energy substrate. Mechanism is multimodal: free radical scavenging, membrane phospholipid stabilization, succinate-driven mitochondrial substrate provision under conditions of compromised respiratory chain function, and modest GABA-A allosteric modulation. The compound is administered orally or by IV/IM injection in clinical use. The Russian clinical evidence base is extensive (used in tens of thousands of patients) but Western-grade randomized trials with standard endpoints are limited.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • FOXO4-DRI Peptide

    Cell-penetrating peptide senolytic

    A retroinverso D-amino acid peptide that disrupts the FOXO4-p53 interaction in senescent cells, selectively triggering apoptosis.

    Abstract

    FOXO4-DRI (FOXO4-D-retroinverso peptide; sequence ltlrkepaseiaqsileayqqgs in D-amino acids; molecular weight approximately 2700 Da) is a designed cell-penetrating peptide senolytic developed by de Keizer and colleagues at the Hubrecht Institute. The compound is a retroinverso peptide derived from the FOXO4 sequence that competitively disrupts the FOXO4-p53 interaction; in senescent cells, FOXO4 sequesters nuclear p53 and prevents apoptosis. The DRI peptide releases p53, which translocates to mitochondria and triggers selective apoptosis in senescent cells while sparing healthy cells (which do not depend on the FOXO4-p53 interaction for survival). Mouse studies (Cell 2017) demonstrated dramatic rejuvenation of fur density, kidney function, and physical performance in aged mice. The retroinverso D-amino acid construction confers protease resistance; cell penetration is supported by an attached penetratin sequence. No human clinical trials at this writing. The compound is a research tool for academic senolytic biology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Davunetide (NAP)

    ADNP-derived octapeptide

    An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

    Abstract

    Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials).

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sulbutiamine

    Synthetic disulfide thiamine derivative

    A lipophilic disulfide thiamine analog that crosses the blood-brain barrier; developed in Japan for asthenia and used as a nootropic.

    Abstract

    Sulbutiamine (isobutyryl thiamine disulfide; CAS 3286-46-2; molecular formula C32H46N8O6S2; molecular weight 702.89) is a synthetic disulfide derivative of thiamine (vitamin B1) developed in Japan in the 1960s and approved in several Asian and European markets under the trade name Arcalion. The compound is structurally a dimer of two thiamine molecules joined by a disulfide bridge, conferring high lipophilicity and improved blood-brain barrier penetration compared to thiamine itself. Mechanism: thiamine prodrug; sulbutiamine is metabolized to thiamine in the brain, raising central thiamine concentrations and supporting thiamine-dependent enzymes (transketolase, pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Clinical use is in psychogenic asthenia and as a nootropic; evidence is from clinical trials with mixed methodology. Plasma half-life is approximately 5 hours. Used as a lipophilic thiamine prodrug in research and nootropic communities.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ARA-290 (Cibinetide)

    EPO-derived helix B peptide

    An 11-amino-acid fragment of erythropoietin’s helix B with tissue-protective activity but without erythropoietic activity.

    Abstract

    ARA-290 (Cibinetide; Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; CAS 1208243-50-8) is an 11-residue peptide derived from the alpha-helix B region of erythropoietin (EPO). The peptide retains the tissue-protective and anti-inflammatory activity of EPO (mediated through the heteromeric EPO/CD131 innate repair receptor) without the erythropoietic activity (mediated through the EPO receptor homodimer). The compound was developed by Araim Pharmaceuticals for diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and other neuropathic pain indications. Phase 2 trials in sarcoidosis-associated SFN showed reductions in neuropathic pain and improvements in autonomic measures.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thymulin

    Zinc-dependent thymic nonapeptide

    A zinc-dependent endogenous thymic nonapeptide secreted by thymic epithelial cells with T-cell maturation activity.

    Abstract

    Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn; molecular weight 857) is a nonapeptide originally isolated by Bach and Goldstein groups in the 1970s. The peptide is endogenously secreted by thymic epithelial cells and requires bound zinc for biological activity. Pharmacology includes promotion of T-cell differentiation, modulation of cytokine balance, and effects on autoimmune and inflammatory processes. The compound has been studied in chronic infections, autoimmune diseases, and cancer immunotherapy adjunct applications, with limited Phase 2 evidence. Available as research peptide.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Latrepirdine (Dimebon)

    Multi-target antihistamine / mitochondrial protectant

    A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

    Abstract

    Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cutamesine (SA-4503)

    Selective sigma-1 receptor agonist

    A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

    Abstract

    Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.